Literature DB >> 27647272

Assessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA.

Marios Spanakis1, Eleftherios Kontopodis2, Sophie Van Cauter3, Vangelis Sakkalis2, Kostas Marias2.   

Abstract

Dynamic-contrast enhanced magnetic resonance imaging (DCE-MRI) is used for detailed characterization of pathology of lesions sites, such as brain tumors, by quantitative analysis of tracer's data through the use of pharmacokinetic (PK) models. A key component for PK models in DCE-MRI is the estimation of the concentration-time profile of the tracer in a nearby vessel, referred as Arterial Input Function (AIF). The aim of this work was to assess through full body physiologically-based pharmacokinetic (PBPK) model approaches the PK profile of gadoteric acid (Gd-DOTA) and explore potential application for parameter estimation in DCE-MRI based on PBPK-derived AIFs. The PBPK simulations were generated through Simcyp(®) platform and the predicted PK parameters for Gd-DOTA were compared with available clinical data regarding healthy volunteers and renal impairment patients. The assessment of DCE-MRI parameters was implemented by utilizing similar virtual profiles based on gender, age and weight to clinical profiles of patients diagnosed with glioblastoma multiforme. The PBPK-derived AIFs were then used to compute DCE-MRI parameters through the Extended Tofts Model and compared with the corresponding ones derived from image-based AIF computation. The comparison involved: (i) image measured AIF of patients vs AIF of in silico profile, and, (ii) population average AIF vs in silico mean AIFs. The results indicate that PBPK-derived AIFs allowed the estimation of comparable imaging biomarkers with those calculated from typical DCE-MRI image analysis. The incorporation of PBPK models and potential utilization of in silico profiles to real patient data, can provide new perspectives in DCE-MRI parameter estimation and data analysis.

Entities:  

Keywords:  AIF; DCE–MRI; Gd-DOTA; Glioblastoma; PBPK; Pharmacokinetics; Simcyp; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27647272     DOI: 10.1007/s10928-016-9493-x

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  54 in total

1.  Physicochemical properties in pharmacokinetic lead optimization.

Authors:  S D Krämer; H Wunderli-Allenspach
Journal:  Farmaco       Date:  2001 Jan-Feb

Review 2.  Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI.

Authors:  Tong San Koh; Sotirios Bisdas; Dow Mu Koh; Choon Hua Thng
Journal:  J Magn Reson Imaging       Date:  2011-10-03       Impact factor: 4.813

3.  The use of a reference tissue arterial input function with low-temporal-resolution DCE-MRI data.

Authors:  M Heisen; X Fan; J Buurman; N A W van Riel; G S Karczmar; B M ter Haar Romeny
Journal:  Phys Med Biol       Date:  2010-08-03       Impact factor: 3.609

Review 4.  Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.

Authors:  A Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2012-05-30       Impact factor: 6.875

5.  Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model.

Authors:  Thomas E Yankeelov; Jeffrey J Luci; Martin Lepage; Rui Li; Laura Debusk; P Charles Lin; Ronald R Price; John C Gore
Journal:  Magn Reson Imaging       Date:  2005-05       Impact factor: 2.546

Review 6.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

7.  Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  Biopharm Drug Dispos       Date:  2014-09-17       Impact factor: 1.627

8.  A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer.

Authors:  Xia Li; E Brian Welch; Lori R Arlinghaus; A Bapsi Chakravarthy; Lei Xu; Jaime Farley; Mary E Loveless; Ingrid A Mayer; Mark C Kelley; Ingrid M Meszoely; Julie A Means-Powell; Vandana G Abramson; Ana M Grau; John C Gore; Thomas E Yankeelov
Journal:  Phys Med Biol       Date:  2011-08-12       Impact factor: 3.609

Review 9.  Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

Authors:  Anwar R Padhani
Journal:  J Magn Reson Imaging       Date:  2002-10       Impact factor: 4.813

10.  Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines.

Authors:  Aurang Z Khawaja; Deirdre B Cassidy; Julien Al Shakarchi; Damian G McGrogan; Nicholas G Inston; Robert G Jones
Journal:  Insights Imaging       Date:  2015-08-08
View more
  3 in total

1.  Fuzzy C-Means Algorithm-Based ARM-Linux-Embedded System Combined with Magnetic Resonance Imaging for Progression Prediction of Brain Tumors.

Authors:  Haibo Wang; Tieshi Song; Liying Wang; Lei Yan; Lei Han
Journal:  Comput Math Methods Med       Date:  2022-03-15       Impact factor: 2.238

2.  Rapid 2D variable flip angle method for accurate and precise T1 measurements over a wide range of T1  values.

Authors:  Beatrice Lena; Clemens Bos; Cyril J Ferrer; Chrit T W Moonen; Max A Viergever; Lambertus W Bartels
Journal:  NMR Biomed       Date:  2021-05-24       Impact factor: 4.044

3.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.

Authors:  Daniel Scotcher; Nicola Melillo; Sirisha Tadimalla; Adam S Darwich; Sabina Ziemian; Kayode Ogungbenro; Gunnar Schütz; Steven Sourbron; Aleksandra Galetin
Journal:  Mol Pharm       Date:  2021-07-20       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.